Breast Cancer Genetics, Immunology, and Immunotherapy: An Interdisciplinary Approach

Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital.  Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research and Technologies, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the Founder of Universal Scientific Education and Research Network (USERN). Prof. Rezaei has already been the Director of more than two hundreds research projects and has designed and participated in several international collaborative projects. Prof. Rezaei is the editor, editorial assistant, or editorial board member of more than fifty international journals. He has edited more than one hundred international books, has presented more than a thousand lectures/posters in congresses/meetings, and has published more than 1,500 scientific papers in the international journals.

Role of miRNAs in Triple-Negative Breast Cancer: Diagnosis, Prognosis, and Treatment.- Approaches to Breast Cancer Immunology and Immunotherapy.- Molecular Genetics of Breast Cancer: From Mechanistic Insights to the Therapeutic Approaches.- Interleukins in the Development and Progression of Breast Cancer.- Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer.- The Prognostic Impact of Tumor-Infiltrated Lymphocytes (TILs) in Breast Cancer.- From Genes to Recovery: Precision Medicine and Its Influence on Multidrug Resistant Breast Cancer.- Recent Progress and Prospects of Immunotherapy in Multidrug-Resistant and Metastatic Breast Cancer Treatment.- Targeting Myeloid Determinants of Breast Cancer.- siRNA Loaded in Drug Delivery Nanosystems as a Strategy for Breast Cancer Treatment.- Nucleic Acid and Drug Dual Agent Nanoplatforms for Breast Cancer.- Oncolytic Virotherapy Against Breast Cancer.- Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development.